IP Verse

Methods Of Treating Inflammatory And Autoimmune Diseases With Natalizumab - EP1991267

The patent EP1991267 was granted to Biogen Idec MA on Dec 20, 2017. The application was originally filed on Mar 2, 2007 under application number EP07751993A. The patent is currently recorded with a legal status of "Revoked".

EP1991267

BIOGEN IDEC MA
Application Number
EP07751993A
Filing Date
Mar 2, 2007
Status
Revoked
Oct 15, 2021
Publication Date
Dec 20, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

PHARMACEUTICAL WORKS POLPHARMASep 20, 2018WICHMANN -

Patent Citations (6) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2004009169
INTERNATIONAL-SEARCH-REPORTUS2004009169
INTERNATIONAL-SEARCH-REPORTUS2006009385
OPPOSITIONUS2004009169
OPPOSITIONWO2006107962
OPPOSITIONWO2007103112

Non-Patent Literature (NPL) Citations (11) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- SCHURMANN ET AL., IMMUNOLOGY, (1999), vol. 97, no. 4, pages 693 - 698
EXAMINATION- Rob C. Aalberse ET AL, "IgG4 breaking the rules", Immunology, (20020101), vol. 105, no. 1, doi:10.1046/j.0019-2805.2001.01341.x, ISSN 0019-2805, pages 9 - 19, XP055115132
INTERNATIONAL-SEARCH-REPORT- ENGELHARDT ET AL., "Therapeutic targeting of alpha4-integrins in chronic inflammatory disease: tipping the scales of risk towards benefit?", EUR. J. IMMUNOLOGY, (2005), vol. 35, pages 2268 - 2273, XP008130272
INTERNATIONAL-SEARCH-REPORT- SCHUURMAN ET AL., "Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites", IMMUNOLOGY, (1999), vol. 97, pages 693 - 698, XP009104479
INTERNATIONAL-SEARCH-REPORT- ALBRECHT ET AL., "Highy active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy", AIDS, (1998), vol. 12, no. 10, pages 1149 - 1154, XP008131053
OPPOSITION- BOMPREZZI et al., Ther Adv Neurol Disord, (20140000), vol. 7, no. 5, pages 227 - 231, XP055520371
OPPOSITION- NIINO et al., "Natalizumab Effects on Immune Cell Responses in Multiple Sclerosis", Annals of Neurology, (20060000), vol. 59, no. 5, pages 748 - 754, XP055520371
OPPOSITION- Patricia Inacio, (20180205), URL: multiplesclerosisnewstoday.com/ 2018/02/05 /actrims2018-ms-natalizumab- extended-interval-dosing-associatedreduction-progressive-multifocal- leukoencephalopathy-risk-touch-registry-data-suggest
OPPOSITION- MIRE-SLUIS et al., Journal of Immunological Methods, (20040000), vol. 289, pages 1 - 16, XP004520874
OPPOSITION- PATTON et al., "An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen", Journal of Immunological Methods, (20050000), vol. 304, pages 189 - 195, XP002588698
SEARCH[ ] - No further relevant documents disclosed

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents